Capecitabine
Gastro-Intestinal Intraepithelial Neoplasia
Rutgers, The State University of New JerseySmall moleculePhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Gastro-Intestinal Intraepithelial Neoplasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Rutgers, The State University of New Jersey | Phase 4 | BB |
9-valent human papillomavirus recombinant vaccine Xiamen University | Phase 3 | B |
Promitil Lipomedix Pharmaceuticals Inc. | Phase 1 | C |
Abi-1968 Antiva Biosciences | Phase 1 | NR |
Same molecule, other indications
Capecitabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →